Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13891680 | 1.00 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL1146896 | 0.87 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL13891599 | 0.86 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL1146890 | 0.86 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL13891600 | 0.85 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL1146563 | 0.85 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL1146830 | 0.84 | GCK (0.72) | GCKKCNH2 | |
| SCHEMBL13891540 | 0.84 | GCK (0.72) | GCKKCNH2 | |
| SCHEMBL1146914 | 0.84 | GCK (0.73) | GCKKCNH2 | |
| SCHEMBL13891603 | 0.84 | GCK (0.73) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | claimed |
| EP-1718624-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | claimed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| EP-2048137-A1 | Benzamide derivatives and their use as glucokinase activating agents. | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1718624-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | disclosed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | GCK, GCKR, GRK4 | GCK 1/4885KCNH2 692/4885 |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | GCK, GCKR, GRK4 | GCK 1/4885KCNH2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.